HDL-C and HDL-C/ApoA-I Predict Long-Term Progression of Glycemia in Established Type 2 Diabetes

被引:60
作者
Waldman, Boris [1 ]
Jenkins, Alicia J.
Davis, Timothy M. E. [2 ]
Taskinen, Marja-Riitta [3 ]
Scott, Russell [4 ]
O'Connell, Rachel L. [1 ]
Gebski, Val J. [1 ]
Ng, Martin K. C. [5 ]
Keech, Anthony C. [1 ,5 ]
机构
[1] Univ Sydney, Sydney Med Sch, NHMRC Clin Trials Ctr, Sydney, NSW 2006, Australia
[2] Univ Western Australia, Sch Med, Fremantle, WA, Australia
[3] Univ Helsinki, Res Programs, Unit Diabet & Obes, Cardiovasc Res Grp,HUCH Heart & Lung Ctr, Helsinki, Finland
[4] Christchurch Hosp, Lipid & Diabet Res Grp, Christchurch, New Zealand
[5] Royal Prince Alfred Hosp, Dept Cardiol, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会; 英国医学研究理事会;
关键词
INSULIN-RESISTANCE ATHEROSCLEROSIS; CARDIOVASCULAR RISK-FACTORS; NUCLEAR-MAGNETIC-RESONANCE; BETA-CELL FUNCTION; LIPOPROTEIN PARTICLE-SIZE; APOLIPOPROTEIN-A-I; GLUCOSE-METABOLISM; FENOFIBRATE INTERVENTION; LIFE-STYLE; CHOLESTEROL;
D O I
10.2337/dc13-2738
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVE Low HDL cholesterol (HDL-C) and small HDL particle size may directly promote hyperglycemia. We evaluated associations of HDL-C, apolipoprotein A-I (apoA-I), and HDL-C/apoA-I with insulin secretion, insulin resistance, HbA(1c), and long-term glycemic deterioration, reflected by initiation of pharmacologic glucose control. RESEARCH DESIGN AND METHODS The 5-year Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study followed 9,795 type 2 diabetic subjects. We calculated baseline associations of fasting HDL-C, apoA-I, and HDL-C/apoA-I with HbA(1c) and, in those not taking exogenous insulin (n = 8,271), with estimated beta-cell function (homeostasis model assessment of b-cell function [HOMA-B]) and insulin resistance (HOMA-IR). Among the 2,608 subjects prescribed lifestyle only, Cox proportional hazards analysis evaluated associations of HDL-C, apoA-I, and HDL-C/apoA-I with subsequent initiation of oral hypoglycemic agents (OHAs) or insulin. RESULTS Adjusted for age and sex, baseline HDL-C, apoA-I, and HDL-C/apoA-I were inversely associated with HOMA-IR (r = -0.233, -0.134, and -0.230; all P < 0.001; n = 8,271) but not related to HbA(1c) (all P > 0.05; n = 9,795). ApoA-I was also inversely associated with HOMA-B (r = -0.063; P = 0.002; n = 8,271) adjusted for age, sex, and HOMA-IR. Prospectively, lower baseline HDL-C and HDL-C/apoA-I levels predicted greater uptake (per 1-SD lower: hazard ratio [HR] 1.13 [CI 1.07-1.19], P < 0.001; and HR 1.16 [CI 1.10-1.23], P < 0.001, respectively) and earlier uptake (median 12.9 and 24.0 months, respectively, for quartile 1 vs. quartile 4; both P < 0.01) of OHAs and insulin, with no difference in HbA(1c) thresholds for initiation (P = 0.87 and P = 0.81). Controlling for HOMA-IR and triglycerides lessened both associations, but HDL-C/apoA-I remained significant. CONCLUSIONS HDL-C, apoA-I, and HDL-C/apoA-I were associated with concurrent insulin resistance but not HbA(1c). However, lower HDL-C and HDL-C/apoA-I predicted greater and earlier need for pharmacologic glucose control.
引用
收藏
页码:2351 / 2358
页数:8
相关论文
共 40 条
  • [1] Role of HDL Cholesterol and Estimates of HDL Particle Composition in Future Development of Type 2 Diabetes in the General Population: The PREVEND Study
    Abbasi, Ali
    Corpeleijn, Eva
    Gansevoort, Ron T.
    Gans, Rijk O. B.
    Hillege, Hans L.
    Stolk, Ronald P.
    Navis, Gerjan
    Bakker, Stephan J. L.
    Dullaart, Robin P. F.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2013, 98 (08) : E1352 - E1359
  • [2] The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]
    Barter, P.
    Best, J.
    Colman, P.
    d'Emden, M.
    Davis, T.
    Drury, P.
    Ehnholm, C.
    Glasziou, P.
    Hunt, D.
    Keech, A.
    Kesaniemi, Y. A.
    Laakso, M.
    Scott, R.
    Simes, R. J.
    Sullivan, D.
    Taskinen, M-R
    Whiting, M.
    Ansquer, J-C
    Fraitag, B.
    Anderson, N.
    Hankey, G.
    Hunt, D.
    Lehto, S.
    Mann, S.
    Romo, M.
    Li, L. P.
    Hennekens, C.
    MacMahon, S.
    Pocock, S.
    Tonkin, A.
    Wilhelmsen, L.
    Forder, P.
    Akauola, H.
    Alford, F.
    Barter, P.
    Beinart, I.
    Best, J.
    Bohra, S.
    Boyages, S.
    Colman, P.
    Connor, H.
    Darnell, D.
    Davis, T.
    Davoren, P.
    Lepre, F.
    De Looze, F.
    d'Emden, M.
    Duffield, A.
    Fassett, R.
    Flack, J.
    [J]. CARDIOVASCULAR DIABETOLOGY, 2004, 3 (1)
  • [3] Glycemic Control Over 5 Years in 4,900 People With Type 2 Diabetes Real-world diabetes therapy in a clinical trial cohort
    Best, James D.
    Drury, Paul L.
    Davis, Timothy M. E.
    Taskinen, Marja-Riitta
    Kesaniemi, Y. Antero
    Scott, Russell
    Pardy, Christopher
    Voysey, Merryn
    Keech, Anthony C.
    [J]. DIABETES CARE, 2012, 35 (05) : 1165 - 1170
  • [4] β-cell ABCA1 influences insulin secretion, glucose homeostasis and response to thiazolidinedione treatment
    Brunham, Liam R.
    Kruit, Janine K.
    Pape, Terry D.
    Timmins, Jenelle M.
    Reuwer, Anne Q.
    Vasanji, Zainisha
    Marsh, Brad J.
    Rodrigues, Brian
    Johnson, James D.
    Parks, John S.
    Verchere, C. Bruce
    Hayden, Michael R.
    [J]. NATURE MEDICINE, 2007, 13 (03) : 340 - 347
  • [5] Calculator HOMA, 2014, HOMA CALCULATOR FAQ
  • [6] Cardiovascular disease risk factors predict the development of type 2 diabetes - The Insulin Resistance Atherosclerosis Study
    D'Agostino, RB
    Hamman, RF
    Karter, AJ
    Mykkanen, L
    Wagenknecht, LE
    Haffner, SM
    [J]. DIABETES CARE, 2004, 27 (09) : 2234 - 2240
  • [7] The emerging role of HDL in glucose metabolism
    Drew, Brian G.
    Rye, Kerry-Anne
    Duffy, Stephen J.
    Barter, Philip
    Kingwell, Bronwyn A.
    [J]. NATURE REVIEWS ENDOCRINOLOGY, 2012, 8 (04) : 237 - 245
  • [8] High-Density Lipoprotein Modulates Glucose Metabolism in Patients With Type 2 Diabetes Mellitus
    Drew, Brian G.
    Duffy, Stephen J.
    Formosa, Melissa F.
    Natoli, Alaina K.
    Henstridge, Darren C.
    Penfold, Sally A.
    Thomas, Walter G.
    Mukhamedova, Nigora
    de Courten, Barbora
    Forbes, Josephine M.
    Yap, Felicia Y.
    Kaye, David M.
    van Hall, Gerrit
    Febbraio, Mark A.
    Kemp, Bruce E.
    Sviridov, Dmitri
    Steinberg, Gregory R.
    Kingwell, Bronwyn A.
    [J]. CIRCULATION, 2009, 119 (15) : 2103 - U134
  • [9] Pancreatic β-cell function relates positively to HDL functionality in well-controlled Type 2 diabetes mellitus
    Dullaart, Robin P. F.
    Annema, Wijtske
    de Boer, Jan Freark
    Tietge, Uwe J. F.
    [J]. ATHEROSCLEROSIS, 2012, 222 (02) : 567 - 573
  • [10] The natural course of β-cell function in nondiabetic and diabetic individuals -: The insulin resistance atherosclerosis study
    Festa, A
    Williams, K
    D'Agostino, R
    Wagenknecht, LE
    Haffner, SM
    [J]. DIABETES, 2006, 55 (04) : 1114 - 1120